BioStream is developing a urine-based platform that combines proteomic analysis with AI-supported interpretation to help clinicians distinguish treatable NPH from neurodegenerative conditions.
The Problem
Up to 10% of the 5.2 million people in the U.S. diagnosed with Alzheimer’s disease may have underlying, treatable NPH.
80% of NPH cases are untreated due to the complex and expensive diagnostic path.
NPH symptoms can resemble Alzheimer’s disease and other neurodegenerative conditions.
The Solution
The planned workflow uses point-of-care collection, centralized proteomic analysis, and a clinician-facing result.
at the clinical point of care
measures a proprietary biomarker panel
supports differential diagnosis within the clinical workflow
Simple collection. Centralized analysis. Clinical insight.
Collect urine sample
Laboratory proteomic analysis
AI-supported interpretation
Result returned to clinician
Objective biomarker data may help clinicians distinguish treatable NPH from dementia.
Ongoing multi-center study with 100+ hydrocephalus samples and 50 dementia controls.
Drop us a message and we’ll get back to you soon.
